The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 10; pp. 3379 - 3382
Main Authors Danilov, Alexey V., Flinn, Ian W., Davids, Matthew S., Gregory, Beth, Bentur, Ohad, Sidransky, David, Brown, Jennifer R.
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.10.2024
Ferrata Storti Foundation
Subjects
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Female
Humans
Isoquinolines - administration & dosage
Isoquinolines - therapeutic use
Letter to the Editor
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Male
Middle Aged
Phosphoinositide-3 Kinase Inhibitors - therapeutic use
Purines - therapeutic use
Recurrence
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-4
Disclosures
JRB has served as a consultant for AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Hutchmed, iOnctura, Janssen, MEI Pharma, and Pharmacyclics, and has received research funding from BeiGene, Gilead, Loxo/Lilly, MEI Pharma, SecuraBio, Sun, and TG Therapeutics. AVD has received consulting fees from AbbVie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Lilly Oncology, Merck, Nurix, and has ongoing research funding from AstraZeneca, Bristol Meyers Squibb, Cyclacel, MEI Pharma, SecuraBio, and Nurix. IWF has received consulting fees from AbbVie, BeiGene, Genentech, Genmab, Kite Pharma, Roche, and Vincerx Pharma, and has received research funding from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation Pharmaceuticals, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, InnoCare Pharma, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo, Marker Therapeutics, Merck, Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Step Pharma, Tessa Therapeutics, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem, Vincerx Pharma, and 2seventy Bio. MSD has received institutional research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics and personal consulting income from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Nuvalent, ONO Pharmaceuticals, Secura Bio, TG Therapeutics, and Takeda. BG and OB are employees of Secura Bio, Inc. DS is a paid consultant to Secura Bio, Inc.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2024.285043